Pharma and healthcare: sector news on Saturday 31 October 2026
Average tone +2.5 (slightly positive) across 3 companies with relevant coverage, from 99 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +8.7 | 78 | Coverage centred on third-quarter results that beat forecasts, driven by cancer drug growth, alongside a $1.5bn annual savings plan and a confident pipeline outlook. |
| GSK | +4.0 | 12 | Coverage centred on third-quarter results, where earnings beat expectations and the dividend was confirmed, with specialty medicines offsetting weaker vaccines. |
| Haleon | −5.2 | 9 | Coverage centred on a share price slide after a company warning, with several brokers cutting price targets and questioning the growth outlook. |
| Convatec | — | 0 | |
| Smith & Nephew | — | 0 |
Strongest stories in the sector
- +10.0 Shares at multi-month high on chief executive's large pipeline potential claim
- +10.0 Sharp share price rise after results
- +10.0 Confident chief executive and rising shares
- +10.0 Large potential from upcoming trial data, shares near breakout
- +10.0 Sharp profit rise and cost savings programme
- +10.0 Shares rallied on earnings beat and cancer drug growth
- +10.0 Shares surged on results, topping index risers
- +10.0 Profit lifted by leading cancer medicines
- +10.0 Long growth outlook backed by pipeline and approvals
- +10.0 Earnings call points to strong cancer drug sales growth
- +10.0 Earnings beat driven by cancer drug sales
- +10.0 Strong share gain despite capped restructuring spend
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.